ALK and neoplasm: These indications can vary with regards to squamous or non-squamous NSCLC, tumour proportion score (TPS) (PD-L1 expression of ≥ 1%; 0–49%; or ≥ 50%), with or without EGFR/ALK mutations, first- or second line, mono- or combination therapy.